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Anemia Is Associated Wlth Worse Symptoms, Greater 
Impairment in Functlonal Capacity, and a Slgnlficant 
Increase in Mortality in Patients With Advanced Heart 
Failure 
Greaa C. Fonarew, Tamare B. Horwich, Michele A. Hamilton, J. Borenstain, UCLA 
Medical Center, Los Angeles, California, Zynx Health Incorporated, Los Angeles. 
California. 
Background: Although it is known that chronic diseases including heart failure (HF) can 
lead to anemia, the role of hemoglobin (Hb) level in the prognosis of patients with estab- 
lished HF has not been fully defined. 
Methods: We analyzed a cohort of 1061 patients with advanced HF (NYHA Class III or 
IV and LVEF < 40%) referred to a single center for management and transplant evalua- 
tion. Hb level was drawn at time of presentation. Patients were divided into Hb quartiles 
(Q): Q1 <12.3; Q2 12.3-13.6; Q3 13.7-14.8; Q4 >14.9 g/dl. 
Results: Mean Hb was 13.6, and values ranged from 7.1 to 19.0. The Hb groups were 
similar in age, medication profile, LVEF, hypertension, diabetes, smoking status, and 
serum sodium. Lower Hb was associated with impaired hemodynamics (higher PCW and 
PA pressures and lower BP), higher BUN and Cr, but lower albumin, cholesterol, and 
BMI. Patients in the lower Hb quartiles were more likely to be NYHA IV (P<0.0001) and 
have lower peak VO2 (P<0.0001). At 1 year, mortality of Q1 was significantly higher than 
Q4 (table). At 5 years, patients with Hb <12.3 had significantly impaired survival com- 
pared to those with Hb > 13.7 (P<0.005). After adjustment for established risk factors, Hb 
was an independent predictor of 5-year mortality (for each 1 g/dl decrease, RR 1.095, CI 
1.015-1.116). 
Conclusion,=: In chronic HF, symptoms, functional status, and survival are impaired by 
relatively mild degrees of anemia. Randomized clinical trials are needed to assess the 
efficacy of correcting anemia in patients with advanced HF. 
One Year Mortality Rates by Quartlle of Hemoglobin 
Hemoglobin Quartile Quartile 1 Quartile 2 Quartile 3 Quartile 4 
(<12.3) (12.3-13.7) (13.7-14.9) (>14.9) 
N 271 253 256 281 
Death or Urgent 109 82 66 65 
Transplant 
Mortality or Urgent 43.5% 36.2% 28.3% 25.2% 
Transplant at 1 Year 
Unadjusted Relative Risk 2.015 1.490 1.099 1.0 
(95%CI) (1.482-2.741) (1.076-2.063) (0.779-1.549) 
P value 0.0001 0.0001 0.592 
Adjusted Relative Risk 1.643 1.412 1.231 1.0 
(95%CI) (1.162-2.323) (0.991-2.014) (0.856-1.770) 
P value 0.005 0.056 0.263 
10:45 a.m. 
858-2 Renal Insuff iciency as a Predictor of Cardiovascular 
Outcome in Hospitalized Patients With De¢ompenseted 
Heart Failure 
Uri Elkavam, on Behalf of the VMAC Study Group, University of Southern California Keck 
School of Medicine, Los Angeles, California. 
Background: The impact of renal function on morbidity and mortality in patients admitted 
for decompensated heart failure (CHF) is not well defined. 
Methods: The effect of baseline renal insufficiency, defined as serum creatinine (Scr) 
>1.5 mg/dL and worsening renal function (increase in Scr >0.5 mg/dL) during the hospi- 
talization, was evaluated in 481 patients with decompensated CHF and randomized into 
the Vasodilation in the Management of CHF (VMAC) Trial. 
Results: Patients with renal insufficiency had higher 1- and 6-month mortality (8.8% vs 
5.3%, p=0.149 and 37.4%, vs 12.3%, p<0.001, respectively), longer hospital stay 
(10.3±8.4 vs 8.2±7.1 days, p=0.003), and an increased 30-day readmission rate (27% vs 
17%, p0.5 mg/dL during the hospitalization was associated with increases in 1- and 6- 
month mortality (15.6% vs 5.6% and 41% vs 21%, respectively, p<0.01 for both) longer 
hospital stay (16±10 vs 8±7 days, p<0.01). The effect of renal insufficiency on 6-month 
mortality (adjusted hazard ratio=2.47, 95% C1=1.6 to 3.7) was an independent predictor 
of poor outcome and was stronger than any other known predictor, including: ventricular 
tachycardia/fibriliation during the hospitalization, diabetes metlitus, ejection fraction, age, 
gender, or ischemic etiology, 
Conclusion: In patients hospitalized for decompensated heart failure, baseline renal 
insufficiency or worsening renal function during the hospitalization has a powerful and 
independent effect on length of hospital stay, rate of rehospitalizations, and 1- and 6- 
month mortality, improvement or preservation of renal function may therefore be an 
important herapeutic goal in the treatment of patients with severe, clecompensated heart 
failure. 
JACC March 6, 2002 
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858-3 Exposure to Glitazone AntidiabeUcs and Risk of Heart 
Failure Among Persons With "P/pe 2 Diabetse: A 
Retrospective Population-Based Cohort Analysis 
Thomas Delea. May Hagiwara, John Edelsberg, Gerry Oster, Po/icyAnalysis Inc. (PAl), 
Brookline, Massachusetts. 
Background: Use of giitazone antidiabetics (troglitazone, rosiglitazone, pioglitazone) in 
patients with type 2 diabetes may result in plasma volume expansion and edema. The 
effects of these drugs on risk of heart failure (HF) are not established, however, 
Methods: We examined the relationship between use of glitazone antidiabetics and risk 
of HF in patients with type 2 diabetes. Data were obtained from an integrated health-care 
insurance claims database representing up to 17 million persons enrolled in approxi- 
mately 35 health plans in the US. The study sample included all persons with >1 claim 
with a diagnosis of type 2 diabetes and >1 claim for an oral antidiabetic drug between 1/ 
95 and 3/01. Those with >1 claim for a glitazone constituted the "exposed' group; for 
these patients, the date of the first claim for a glitazone was designated the "index date'. 
Five unexposed controls were randomly selected for each exposed patient and arbitrarily 
assigned the same index date. Patients with a diagnosis of HF in the 12 months prior to 
the index date were excluded as were those without continuous enrollment during this 
period. Cox proportional hazards regression was used to compare the risk of HF post- 
index date among exposed vs unexposed patients adjusting for potential confounders 
including age, history of complications of diabetes and dsk factors for HF, receipt of 
selected medications for diabetes and HF, and pre-index health-care costs. 
Results: We identified a total of 8,268 patients with type 2 diabetes who received glita- 
zones, whom we matched to 41,440 unexposed controls. Patients receiving glitazones 
were older, more likely to have complications of diabetes and risk factors for HF and to 
have received insulin; they also had higher pre-index health-care costs (p<.05 for all fac- 
tors). Risk of HF post-index date was 4.5% in glitazone patients and 2.6% in controls 
(mean follow-up=8.5 months). After adjusting for potential confounders, use of glitazonec 
was associated with an increased risk of HF (hazard ratio=1.61, p<.001). 
Conclusion: Use of glitazone antidiabetics may increase the risk of HF independently of 
age and other risk factors. Further research is needed to confirm these findings. 
11:15 a.m. 
858-4 Impact of Body Mass Index on the Risk of Heart Failure: 
The Framingham Heart Study 
Satish Kenchaiah, Daniel Levy, Jane C. Evans, Emetia J. Benjamin, Martin G. Larsen, 
Peter W. Wilson, William B. Kannel, Ramachandran Vasan, NHLBI's Framingham Heart 
Study, Framingham, Massachusetts, Boston University School of Medicine, Boston, 
Massachusetts. 
Background: Heart failure (HF) and overweight/obesity are major and growing public 
health problems. While extreme obesity has been associated with HF, the relations of 
overweight and common degrees of obesity to HF risk are unclear. 
Methods: We investigated the relation of body mass index (BMI) to HF incidence among 
5902 (mean age 55 years, 54% women) Framingham Study subjects. We used sex-spe- 
cific muitivadable Cox regression models with BMI evaluated both as a continuous and 
as a categorical variable. 
Results: Over a mean follow-up of 14 years, 498 subjects developed HF (258 women). 
After adjustment for age, cigarette smoking, hypertension, diabetes, valve disease, and 
total cholesterol at baseline, as well as myocardial infarction at baseline and follow up, 
there was a 5-7% increase in HF risk for every 1 kg/m 2 increment in BMI (hazard ratio 
1.05, 95% CI 1.01-1.09 in men; and 1.07, 95% CI 1.04-1.1 in women). A substantial 
increase in HF risk was also noted across conventional BMI categories (Table). A striking 
finding was a near doubling of HF risk in obese subjects. 
Conclusion: In our large community based sample, BMI was associated with increased 
HF risk without any apparent hreshold. The residual excess HF risk suggests a unique 
influence of overweight/obesity on development of HF. In light of the high prevalence of 
overweight (32%) and obesity (22.5%) in the United States, strategies to prevent the 
development of excess weight, and to reduce body weight to optimal levels may 
decrease the population burden of HE 
BMI and HF risk 
BMI (kg/m =) Hazard Ratio (95% CI) 
Man Women 
Normal (18.5 to <28) 1.0 (referent) 1.0 (referent) 
Overweight (25 to <30) 1. f 9 (0.87-1.62) 1.43 (1.07-1.92) 
Obese (_>30) 1.93 (1.32-2.82) 2.01 (1.44-2,80) 
Trend across categories p=0.0014 p=0.0001 
